Alchemab Therapeutics has appointed Ulrich Wendt, PhD MBA, as Chief Business Officer (CBO). As a proven dealmaker and strategist, Wendt brings more than a decade of experience in delivering high-value partnerships across all pipeline stages.

His appointment builds on Alchemab’s recent pharma licensing deals, Series A funding extension, and progression of their first asset into clinical trials.

“As CBO, Ulrich will lead Alchemab’s business development and alliance management, working closely with the executive team to expand the company’s partnerships across biopharma and adjacent sectors,” said Jane Osbourn, CEO and Co-Founder of Alchemab. “He will also help guide our corporate strategy as we continue scaling our AI-enabled platform capabilities.”

Experience

Before joining Alchemab, Wendt served as Global Head of Business Development Immunology at Sanofi. Prior to this, he drove global Business Development for Sanofi’s diabetes and primary care business units and oversaw global search & evaluation and alliance management teams in cardiometabolic disease.

With academic roots in biostructure and biophysics, Wendt earned his PhD from Freiburg University, completed postdoctoral training at UC Berkeley and Genentech, and gained an MBA from IMD, Lausanne.

“Alchemab’s discovery platform positions the company at the intersection of experimental and AI-enabled discovery,” Dr Wendt said. “Within the last two years the company has advanced into clinical trials and delivered a stream of preclinical candidates with novel target biology. I am excited to be joining Jane and the Alchemab team at this pivotal time to help position the company for the next wave of growth.”